Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Public ClinicalTrials.gov record NCT07745361. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.
Study identification
- NCT ID
- NCT07745361
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2026
- Primary completion
- Sep 30, 2027
- Completion
- Mar 31, 2028
- Last update posted
- Aug 23, 2026
2026 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| START Los Angeles | Los Angeles | California | 90025 | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | Not yet recruiting |
| Rocky Mountain Cancer Center | Colorado Springs | Colorado | 80907 | Not yet recruiting |
| Kansas University Cancer Center | Kansas City | Kansas | 66160 | Not yet recruiting |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | Not yet recruiting |
| Henry Ford | Novi | Michigan | 48377 | Not yet recruiting |
| XCancer Omaha | Omaha | Nebraska | 68130 | Recruiting |
| START New Jersey | East Brunswick | New Jersey | 08816 | Recruiting |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | Not yet recruiting |
| Lancaster Urology | Lancaster | Pennsylvania | 17601 | Not yet recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Not yet recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Not yet recruiting |
| University of Washington Medical Center | Seattle | Washington | 98195 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07745361, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07745361 live on ClinicalTrials.gov.